HPIL Holding and the World Traditional Okinawa Karate Federation
Dec 21, 2017 12:32 pm UTC| Business
SANFORD, MI, Dec. 21, 2017 -- HPIL HOLDING (the “Company”) (OTC Pink: HPIL) has been informed by its licensor the World Traditional Fudokan Shotokan Karate-Do Federation (WTFSKF) has changed its name to the World...
Dec 21, 2017 12:30 pm UTC| Business
BEVERLY, Mass., Dec. 21, 2017 -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces all patient follow-up visits have been completed in its Phase...
Zenergy Brands Announces New Carbon Footprint Reduction Counter
Dec 21, 2017 12:30 pm UTC| Business
DALLAS, Dec. 21, 2017 -- Zenergy Brands, Inc. (OTCQB: ZNGY), the nation’s leading next-generation utility, is excited to announce today its new Carbon Footprint Reduction Counter on its new corporate website,...
Dec 21, 2017 12:30 pm UTC| Business
PHOENIX, Dec. 21, 2017 -- Uptick Newswire is the sole producer of the Uptick Network “Stock Day” Podcast and after airing back in January 2016 CEO and host Everett Jolly has interviewed hundreds of CEO’s within the...
Amicus Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 21, 2017 12:30 pm UTC| Business
CRANBURY, N.J., Dec. 21, 2017 -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 36th Annual J.P. Morgan Healthcare...
Dec 21, 2017 12:01 pm UTC| Business
ZUG, Switzerland, Dec. 21, 2017 -- Transocean Ltd. (NYSE:RIG) announced today that the harsh environment semisubmersible Transocean Spitsbergen was awarded a 22-well contract with an estimated duration of 33 months;...
Arix Bioscience PLC: Arix Bioscience co-leads $30 million financing for Aura Biosciences
Dec 21, 2017 12:01 pm UTC| Business
Arix Bioscience co-leads $30 million financing for Aura Biosciences Funding to advance development of Aura's novel treatment to selectively destroy cancer cells; lead candidate AU-011 currently in Phase 1b/2 study to...